lenograstim
Sign in to saveLenograstim is a recombinant granulocyte colony-stimulating factor which functions as an immunostimulator. It is developed by Chugai Pharmaceuticals under the brand name Granocyte.
Chemical data
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Protein
- Indications
- multiple myeloma, acute myeloid leukemia, diffuse large B-cell lymphoma, prostate cancer
via ChEMBL · EBI
Research
420 papers- Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.The Lancet. Oncology · 2012
- Lenograstim: a review of its use in chemotherapy-induced neutropenia, for acceleration of neutrophil recovery following haematopoietic stem cell transplantation and in peripheral blood stem cell mobilization.Drugs · 2011
- Lenograstim. A review of its pharmacological properties and therapeutic efficacy in neutropenia and related clinical settings.Drugs · 1995
- G-CSF: filgrastim, lenograstim and biosimilars.Expert opinion on biological therapy · 2014
- Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings.Drugs · 2000
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Has use
- medication
Show 2 more facts
- defined daily dose
- 0.35
- subject has role
- immunologic adjuvant
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
1 sectionsContents
- References
Lenograstim is a recombinant granulocyte colony-stimulating factor which functions as an immunostimulator. It is developed by Chugai Pharmaceuticals under the brand name Granocyte.
== References ==
Excerpted from Wikipedia’s “lenograstim” article, available under the CC BY-SA 4.0 licence.
Available in 6 languages
via Wikidata sitelinks · CC0